source
- Eli Lilly's Alzheimer's drug mevidalen fails Phase 2 trialEli Lilly conducted a Phase 2 trial of mevidalen, a dopamine-modulating compound, in patients with mild to moderate Alzheimer's disease. The study did not meet its primary efficacy endpoints, indi…
- Heidi Overton’s FDA nomination stalls as Senate HELP Committee vote failsHeidi Overton, the Trump administration’s pick for FDA commissioner, faced a decisive vote before the Senate HELP Committee less than a day after her testimony. The committee’s deliberations were…